{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:10:46Z","timestamp":1792293046809,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jaad.2016.11.010","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T12:51:22Z","timestamp":1497358282000},"page":"17-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"title":["Current and emerging treatments for vitiligo"],"prefix":"10.1016","volume":"77","author":[{"given":"Michelle","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.11.010_bib1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","article-title":"Vitiligo is not a cosmetic disease","volume":"73","author":"Ezzedine","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.11.010_bib3","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jaad.2015.12.049","article-title":"Follicular vitiligo: a report of 8 cases","volume":"74","author":"Gan","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13555-013-0028-8","article-title":"Narrow band-ultraviolet B versus clobetasol propionate foam in the treatment of vitiligo: a retrospective study","volume":"3","author":"Stinco","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2016.11.010_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib6","first-page":"CD003263","article-title":"Interventions for vitiligo","volume":"2","author":"Whitton","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2016.11.010_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/archderm.142.7.927","article-title":"A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo","volume":"142","author":"Mehrabi","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/0378-6323.42905","article-title":"An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad\/narrowband UVB phototherapy in progressive vitiligo","volume":"74","author":"Rath","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2016.11.010_bib10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1468-3083.2007.02283.x","article-title":"Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study","volume":"21","author":"Bhatnagar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.11.010_bib11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archderm.143.5.578","article-title":"Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy","volume":"143","author":"Yones","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1468-3083.2006.02035.x","article-title":"Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study","volume":"21","author":"Bhatnagar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.11.010_bib13","first-page":"165","article-title":"Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5\u2032,8-trimethylpsoralen, and psoralen in vitiligo","volume":"66","author":"Pathak","year":"1984","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.jaad.2016.11.010_bib14","first-page":"292","article-title":"Immunohistochemical study before and after narrow band (311 nm) UVB treatment in vitiligo","volume":"18","author":"De Francesco","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1346-8138.2006.00079.x","article-title":"Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo","volume":"33","author":"Arca","year":"2006","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-4632.2009.03928.x","article-title":"Therapeutic evaluation of UVB-targeted phototherapy in vitiligo that affects less than 10% of the body surface area","volume":"48","author":"Welsh","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2230.2005.01837.x","article-title":"Narrow-band UVB for the treatment of generalized vitiligo in children","volume":"30","author":"Kanwar","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-4632.2004.02329.x","article-title":"Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy","volume":"44","author":"Kanwar","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0190-9622(00)90133-6","article-title":"Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy","volume":"42","author":"Njoo","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaad.2016.12.041","article-title":"The vitiligo working group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo","volume":"76","author":"Mohammad","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1600-0781.2011.00587.x","article-title":"The effect of 308nm excimer laser on segmental vitiligo: a retrospective study of\u00a080 patients with segmental vitiligo","volume":"27","author":"Do","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2016.11.010_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2015.04.008","article-title":"Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: a retrospective study of 159 patients","volume":"73","author":"Bae","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2310\/7750.2013.12053","article-title":"Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo","volume":"17","author":"Kanwar","year":"2013","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-4362.1993.tb02754.x","article-title":"Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease","volume":"32","author":"Pasricha","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib25","first-page":"18","article-title":"Evaluation of five different regimes for the treatment of vitiligo","volume":"55","author":"Pasricha","year":"1989","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2016.11.010_bib26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1067\/mjd.2001.113475","article-title":"Oral dexamethasone pulse treatment for vitiligo","volume":"44","author":"Radakovic-Fijan","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000433424","article-title":"A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo","volume":"231","author":"Singh","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2016.11.010_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor-alpha in vitiligo: direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jaad.2016.11.010_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-alpha inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib30","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-alpha agents","volume":"11","author":"Alghamdi","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/dth.12002","article-title":"Deterioration of vitiligo\u00a0and new onset of halo naevi observed in two patients\u00a0receiving adalimumab","volume":"26","author":"Maruthappu","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2016.11.010_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2310\/7750.2011.10068","article-title":"Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab","volume":"15","author":"Alghamdi","year":"2011","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","article-title":"Why treatments do(n't) work in vitiligo: an autoinflammatory perspective","volume":"14","author":"Speeckaert","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2016.11.010_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000102044","article-title":"Etanercept in the treatment of vitiligo","volume":"215","author":"Rigopoulos","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2016.11.010_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-4362.1979.tb01924.x","article-title":"Cyclophosphamide and vitiligo","volume":"18","author":"Gokhale","year":"1979","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1468-3083.2006.01546.x","article-title":"Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo","volume":"20","author":"Goktas","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.11.010_bib37","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1365-2133.2001.04286.x","article-title":"Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study","volume":"145","author":"Ermis","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40257-015-0153-5","article-title":"Alternative systemic treatments for vitiligo: a review","volume":"16","author":"Cohen","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2133.2011.10351.x","article-title":"A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs. clobetasol propionate 0.05% in childhood vitiligo","volume":"165","author":"Ho","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib40","first-page":"88","article-title":"Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo","volume":"15","author":"Coskun","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib41","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1365-4632.2011.05454.x","article-title":"Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study","volume":"51","author":"Sapam","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2230.2007.02514.x","article-title":"Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial","volume":"32","author":"Dell'Anna","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2133.2004.06321.x","article-title":"Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients","volume":"152","author":"Hofer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib44","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1089\/pho.2007.2086","article-title":"Optimal frequency of treatment with the 308-nm excimer laser for vitiligo on the face and neck","volume":"25","author":"Shen","year":"2007","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","article-title":"Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy","volume":"56","author":"Nicolaidou","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib46","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study","volume":"135","author":"Cavalie","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jaad.2011.05.002","article-title":"Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States","volume":"66","author":"Huggins","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2016.04.007","article-title":"Twelve-month and sixty-month outcomes of noncultured cellular grafting for vitiligo","volume":"75","author":"Gan","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib49","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1365-2133.2010.10014.x","article-title":"Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus","volume":"163","author":"van Geel","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0019-5154.53196","article-title":"Tissue grafts in vitiligo surgery - past, present, and future","volume":"54","author":"Khunger","year":"2009","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1365-4362.2003.01628.x","article-title":"Melanocyte-keratinocyte cell transplantation for stable vitiligo","volume":"42","author":"Mulekar","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archderm.135.4.407","article-title":"Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris","volume":"135","author":"Njoo","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib53","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaad.2003.11.085","article-title":"The minigrafting test for vitiligo: validation of a predicting tool","volume":"51","author":"Falabella","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib54","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0190-9622(95)90131-0","article-title":"The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation","volume":"32","author":"Falabella","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2016.11.010_bib55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bjd.12532","article-title":"Surgical interventions for vitiligo: an evidence-based review","volume":"169","author":"Mulekar","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib56","series-title":"Surgical Management of Vitiligo","author":"Gupta","year":"2007"},{"key":"10.1016\/j.jaad.2016.11.010_bib57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1524-4725.2011.02171.x","article-title":"Characterization of clinical response in patients with vitiligo undergoing autologous epidermal punch grafting","volume":"38","author":"Feetham","year":"2012","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib58","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jaad.2004.06.041","article-title":"Surgical pearl: standardized suction syringe for epidermal grafting","volume":"52","author":"Gupta","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib59","first-page":"843","article-title":"Rapid induction of suction blisters by intra-cavity positive pressure enhancement","volume":"37","author":"Gupta","year":"2011","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-2077.158439","article-title":"Role of recipient-site preparation techniques and post-operative wound dressing in the surgical management of vitiligo","volume":"8","author":"Al-Hadidi","year":"2015","journal-title":"J\u00a0Cutan Aesthet Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1524-4725.1995.tb00176.x","article-title":"Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft","volume":"21","author":"Agrawal","year":"1995","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib62","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1067\/mjd.2001.111334","article-title":"Surgical pearl: composite film and graft unit for the recipient area dressing after split-thickness skin grafting in vitiligo","volume":"44","author":"Malakar","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib63","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1365-4632.2012.05513.x","article-title":"Smashed skin grafting or smash grafting - a novel method of vitiligo surgery","volume":"51","author":"Krishnan","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib64","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/DSS.0000000000000709","article-title":"Use of suction blisters for noncultured epidermal suspension grafting in patients with vitiligo","volume":"42","author":"Jeong","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib65","first-page":"45","article-title":"Treatment of vitiligo lesions by ReCell vs. conventional melanocyte-keratinocyte transplantation: a pilot study","volume":"158","author":"Mulekar","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib66","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jaad.2015.03.036","article-title":"Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: a randomized controlled pilot study","volume":"73","author":"Komen","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib67","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12007","article-title":"Comparison between autologous noncultured epidermal cell suspension\u00a0and suction blister epidermal grafting in stable vitiligo: a randomized study","volume":"167","author":"Budania","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clindermatol.2007.10.009","article-title":"Permanent makeup: indications and complications","volume":"26","author":"De Cuyper","year":"2008","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib69","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/ajd.12313","article-title":"Adverse effects\u00a0of\u00a0topical corticosteroids in paediatric eczema: Australasian consensus statement","volume":"56","author":"Mooney","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib70","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic\u00a0dermatitis and the role of topical treatment: a systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib71","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/archderm.140.12.1542-b","article-title":"Alcohol intolerance and facial flushing in patients treated with topical tacrolimus","volume":"140","author":"Milingou","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib72","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.11.010_bib73","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ng.411","article-title":"Genome-wide association study identifies three loci associated with melanoma risk","volume":"41","author":"Bishop","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaad.2016.11.010_bib74","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1468-3083.2006.01899.x","article-title":"Association of vitiligo with HLA-A2: a meta-analysis","volume":"21","author":"Liu","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.11.010_bib75","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.jaad.2013.01.012","article-title":"Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma","volume":"69","author":"Alonso-Castro","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib76","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2016.11.010_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.det.2016.11.003","article-title":"Skin cancer risk (nonmelanoma skin cancers\/melanoma) in vitiligo patients","volume":"35","author":"Rodrigues","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2016.11.010_bib79","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib80","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/00015550410026948","article-title":"No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study","volume":"84","author":"Weischer","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.11.010_bib81","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/0001555572305306","article-title":"PUVA treatment of vitiligo: a retrospective study of 59 patients","volume":"72","author":"Wildfang","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.11.010_bib82","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archderm.1995.01690180114025","article-title":"Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo","volume":"131","author":"Halder","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib83","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jaad.2008.09.033","article-title":"Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo","volume":"60","author":"Hexsel","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib84","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/000155598442944","article-title":"On the association between vitiligo and malignant melanoma","volume":"78","author":"Lindelof","year":"1998","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2016.11.010_bib85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000057881","article-title":"Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed caucasian patients with vitiligo","volume":"204","author":"Schallreuter","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2016.11.010_bib86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib87","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jaad.2011.10.022","article-title":"Long-term prognosis of vitiligo patients on narrowband UVB phototherapy","volume":"66","author":"Park","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib88","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib89","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-4632.2004.02186.x","article-title":"UVB phototherapy and skin cancer risk: a review of the literature","volume":"44","author":"Lee","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib90","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and\u00a0narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib91","first-page":"343","article-title":"Interfering with the IFN-gamma\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.jaad.2016.11.010_bib92","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy","volume":"151","author":"King","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib93","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib94","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibtor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib95","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/archderm.1940.01490180002001","article-title":"Occupational leukoderma","volume":"42","author":"Oliver","year":"1940","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib96","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/archderm.1985.01660090055013","article-title":"Dermatitis produced by applications of monobenzone in patients with active vitiligo","volume":"121","author":"Nordlund","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2016.11.010_bib97","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archopht.1983.01040010066010","article-title":"Corneal and conjunctival effects of monobenzone in patients with vitiligo","volume":"101","author":"Hedges","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaad.2016.11.010_bib98","first-page":"969","article-title":"Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis","volume":"27","author":"Kim","year":"2001","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2016.11.010_bib99","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1600-0749.2006.00334.x","article-title":"Hypopigmenting agents: an updated review on biological, chemical and clinical aspects","volume":"19","author":"Solano","year":"2006","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaad.2016.11.010_bib100","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1468-3083.2010.03876.x","article-title":"Depigmentation therapies for normal skin in vitiligo universalis","volume":"25","author":"AlGhamdi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:42:37Z","timestamp":1759272157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216310957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0190962216310957"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.11.010","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging treatments for vitiligo","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(17)31742-5","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}